NPPA Extends Price Cap on Knee Implants Until November 15, 2025

Published On 2025-09-16 15:00 GMT   |   Update On 2025-09-16 15:00 GMT
Advertisement

New Delhi: The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has extended the applicability of ceiling prices for orthopaedic knee implants used in knee replacement systems for a further two months, i.e., up to 15th November 2025.

The Authority had originally notified the ceiling prices of orthopaedic knee implants vide S.O. 2668(E), dated 16th August 2017, under which maximum retail prices were fixed for various categories of knee replacement systems. These prices were periodically revised and extended, with the last extension issued via notification S.O. 3869(E), dated 10th September 2024, which was valid till 15th September 2025.

Advertisement

According to the latest notification S.O. 4171(E), dated 15th September 2025, NPPA stated:

"Now, therefore, the National Pharmaceutical Pricing Authority hereby extends the period for which the notification number S.O. 3869(E), dated the 10th September, 2024 shall be in force in respect of Orthopaedic Knee Implants for Knee Replacement System for a further period of up to two months beyond the 15th September, 2025, i.e., up to the 15th November, 2025, unless amended by a subsequent notification."

The Authority also clarified that the Notes (b) to (t) of the original 2017 order (S.O. 2668(E)) shall continue to remain in force during this extension period.

The decision comes while representations from manufacturers and industry associations regarding revision of ceiling prices are still under consideration by NPPA.

NPPA had capped the prices of knee implants in 2017 to curb exorbitant costs, bringing down overall procedure expenses for patients by up to 70%. The move was hailed as a landmark step in medical device price regulation. The Authority has since been reviewing industry feedback and extending the notified prices from time to time to maintain regulatory stability.

To view the official notice click the link below:

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News